Day One Biopharmaceuticals Inc
NASDAQ:DAWN
Income Statement
Earnings Waterfall
Day One Biopharmaceuticals Inc
Income Statement
Day One Biopharmaceuticals Inc
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
8
N/A
|
102
+1 145%
|
131
+29%
|
162
+23%
|
188
+16%
|
134
-29%
|
|
| Gross Profit | |||||||||||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(2)
|
(5)
|
(8)
|
(11)
|
(14)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
7
N/A
|
100
+1 231%
|
126
+26%
|
154
+22%
|
176
+15%
|
120
-32%
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(14)
|
(28)
|
(41)
|
(57)
|
(73)
|
(84)
|
(106)
|
(126)
|
(147)
|
(165)
|
(178)
|
(189)
|
(206)
|
(227)
|
(300)
|
(311)
|
(343)
|
(237)
|
(288)
|
(285)
|
|
| Selling, General & Administrative |
(5)
|
(7)
|
(12)
|
(20)
|
(29)
|
(38)
|
(47)
|
(55)
|
(61)
|
(67)
|
(69)
|
(70)
|
(76)
|
(84)
|
(97)
|
(108)
|
(115)
|
(118)
|
(117)
|
(116)
|
|
| Research & Development |
(9)
|
(21)
|
(29)
|
(37)
|
(44)
|
(46)
|
(59)
|
(71)
|
(86)
|
(98)
|
(108)
|
(119)
|
(131)
|
(143)
|
(203)
|
(203)
|
(228)
|
(227)
|
(171)
|
(169)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
108
|
0
|
0
|
|
| Operating Income |
(14)
N/A
|
(28)
-104%
|
(41)
-47%
|
(57)
-38%
|
(73)
-28%
|
(84)
-16%
|
(106)
-25%
|
(126)
-19%
|
(147)
-16%
|
(165)
-12%
|
(178)
-8%
|
(189)
-7%
|
(206)
-9%
|
(227)
-10%
|
(293)
-29%
|
(211)
+28%
|
(217)
-3%
|
(84)
+62%
|
(112)
-34%
|
(166)
-48%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
(30)
|
(30)
|
(30)
|
(29)
|
0
|
0
|
0
|
2
|
5
|
8
|
11
|
15
|
17
|
18
|
19
|
19
|
20
|
20
|
21
|
20
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
108
|
108
|
108
|
0
|
0
|
0
|
|
| Total Other Income |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
1
|
1
|
1
|
1
|
(0)
|
|
| Pre-Tax Income |
(44)
N/A
|
(58)
-32%
|
(71)
-23%
|
(86)
-22%
|
(73)
+16%
|
(84)
-16%
|
(105)
-25%
|
(124)
-18%
|
(142)
-15%
|
(157)
-10%
|
(166)
-6%
|
(175)
-5%
|
(189)
-8%
|
(209)
-11%
|
(166)
+21%
|
(84)
+50%
|
(88)
-6%
|
(62)
+30%
|
(89)
-44%
|
(145)
-63%
|
|
| Net Income | |||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
(1)
|
(7)
|
(7)
|
(6)
|
(6)
|
|
| Income from Continuing Operations |
(44)
|
(58)
|
(71)
|
(86)
|
(73)
|
(84)
|
(105)
|
(124)
|
(142)
|
(157)
|
(166)
|
(175)
|
(189)
|
(209)
|
(167)
|
(84)
|
(95)
|
(69)
|
(95)
|
(152)
|
|
| Income to Minority Interest |
3
|
4
|
(96)
|
(97)
|
(98)
|
(99)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
(41)
N/A
|
(54)
-34%
|
(167)
-208%
|
(183)
-10%
|
(171)
+7%
|
(183)
-7%
|
(105)
+42%
|
(124)
-18%
|
(142)
-15%
|
(157)
-10%
|
(166)
-6%
|
(175)
-5%
|
(189)
-8%
|
(209)
-11%
|
(167)
+20%
|
(84)
+50%
|
(95)
-13%
|
(69)
+28%
|
(95)
-38%
|
(152)
-60%
|
|
| EPS (Diluted) |
-0.67
N/A
|
-0.9
-34%
|
-2.69
-199%
|
-3.18
-18%
|
-4.62
-45%
|
-3.13
+32%
|
-1.73
+45%
|
-1.74
-1%
|
-2.17
-25%
|
-2.17
N/A
|
-2.21
-2%
|
-2.03
+8%
|
-2.37
-17%
|
-2.41
-2%
|
-1.92
+20%
|
-0.86
+55%
|
-1.02
-19%
|
-0.66
+35%
|
-0.9
-36%
|
-1.48
-64%
|
|